• Je něco špatně v tomto záznamu ?

Trends in the Recent Patent Literature on Cholinesterase Reactivators (2016-2019)

AA. de Castro, LC. Assis, FV. Soares, K. Kuca, DA. Polisel, EFF. da Cunha, TC. Ramalho

. 2020 ; 10 (3) : . [pub] 20200312

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012798

Grantová podpora
CAPES/MD Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Ministério da Defesa - International
Excellence PrF UHK UHK - International CEP - Centrální evidence projektů

Acetylcholinesterase (AChE) is the key enzyme responsible for deactivating the ACh neurotransmitter. Irreversible or prolonged inhibition of AChE, therefore, elevates synaptic ACh leading to serious central and peripheral adverse effects which fall under the cholinergic syndrome spectra. To combat the toxic effects of some AChEI, such as organophosphorus (OP) nerve agents, many compounds with reactivator effects have been developed. Within the most outstanding reactivators, the substances denominated oximes stand out, showing good performance for reactivating AChE and restoring the normal synaptic acetylcholine (ACh) levels. This review was developed with the purpose of covering the new advances in AChE reactivation. Over the past years, researchers worldwide have made efforts to identify and develop novel active molecules. These researches have been moving farther into the search for novel agents that possess better effectiveness of reactivation and broad-spectrum reactivation against diverse OP agents. In addition, the discovery of ways to restore AChE in the aged form is also of great importance. This review will allow us to evaluate the major advances made in the discovery of new acetylcholinesterase reactivators by reviewing all patents published between 2016 and 2019. This is an important step in continuing this remarkable research so that new studies can begin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012798
003      
CZ-PrNML
005      
20210507101644.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biom10030436 $2 doi
035    __
$a (PubMed)32178264
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a de Castro, Alexandre A $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil
245    10
$a Trends in the Recent Patent Literature on Cholinesterase Reactivators (2016-2019) / $c AA. de Castro, LC. Assis, FV. Soares, K. Kuca, DA. Polisel, EFF. da Cunha, TC. Ramalho
520    9_
$a Acetylcholinesterase (AChE) is the key enzyme responsible for deactivating the ACh neurotransmitter. Irreversible or prolonged inhibition of AChE, therefore, elevates synaptic ACh leading to serious central and peripheral adverse effects which fall under the cholinergic syndrome spectra. To combat the toxic effects of some AChEI, such as organophosphorus (OP) nerve agents, many compounds with reactivator effects have been developed. Within the most outstanding reactivators, the substances denominated oximes stand out, showing good performance for reactivating AChE and restoring the normal synaptic acetylcholine (ACh) levels. This review was developed with the purpose of covering the new advances in AChE reactivation. Over the past years, researchers worldwide have made efforts to identify and develop novel active molecules. These researches have been moving farther into the search for novel agents that possess better effectiveness of reactivation and broad-spectrum reactivation against diverse OP agents. In addition, the discovery of ways to restore AChE in the aged form is also of great importance. This review will allow us to evaluate the major advances made in the discovery of new acetylcholinesterase reactivators by reviewing all patents published between 2016 and 2019. This is an important step in continuing this remarkable research so that new studies can begin.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    12
$a reaktivátory cholinesterázy $x chemie $x terapeutické užití $7 D002801
650    _2
$a GPI-vázané proteiny $x metabolismus $7 D058851
650    _2
$a lidé $7 D006801
650    _2
$a oximy $x chemie $x terapeutické užití $7 D010091
650    _2
$a patenty jako téma $7 D010330
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Assis, Letícia C $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil
700    1_
$a Soares, Flávia V $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Polisel, Daniel A $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil
700    1_
$a da Cunha, Elaine F F $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil
700    1_
$a Ramalho, Teodorico C $u Department of Chemistry, Federal University of Lavras, Lavras 37200-000, Brazil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
773    0_
$w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 10, č. 3 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32178264 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101644 $b ABA008
999    __
$a ok $b bmc $g 1651043 $s 1133177
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 3 $e 20200312 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
GRA    __
$a CAPES/MD $p Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Ministério da Defesa $2 International
GRA    __
$a Excellence PrF UHK $p UHK $2 International
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace